Evommune terminates oral drug’s development in CSU
While Evommune is terminating development of the oral drug in CSU, trials in AD and migraine prophylaxis will continue.
30 June 2026
30 June 2026
While Evommune is terminating development of the oral drug in CSU, trials in AD and migraine prophylaxis will continue.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.